Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

ProQR Therapeutics NV (PRQR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow ProQR Therapeutics NV's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.020 +0.020    +1.00%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
2.099
+0.079
+3.891%
18:30:06 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 176,222
  • Bid/Ask: 1.990 / 2.100
  • Day's Range: 1.990 - 2.120
ProQR Therapeutics NV 2.020 +0.020 +1.00%

ProQR Therapeutics NV Company Profile

 
Get an in-depth profile of ProQR Therapeutics NV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Contact Information

Address Zernikedreef 9
Leiden, 2333 CK
Netherlands
Phone 31 88 166 7000
Fax -

Top Executives

Name Age Since Title
Donald S. Fong - 2020 Member of Scientific Advisory Board
Bart Filius 51 2019 Independent Supervisory Board Member
James S. Shannon 65 2016 Independent Member of Supervisory Board & Chairman of Scientific Advisory Board
Domenico Valerio 66 2014 Founder & Independent Chairman of Supervisory Board
Theresa Marie Heggie 64 2021 Supervisory Board Member
Alison F. Lawton 63 2014 Independent Member of Supervisory Board
Peter A. Beal - 2018 Member Scientific Advisory Board
Phillip D. Zamore - 2017 Member of Scientific Advisory Board
Yi-Tao Yu - 2018 Member of Scientific Advisory Board
Martin A. Maier - 2020 Member of Scientific Advisory Board
Begona Carreno 53 2023 Supervisory Board Member
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PRQR Comments

Write your thoughts about ProQR Therapeutics NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nhat Doan
Nhat Doan Dec 28, 2022 5:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🔔 Test Can Not SHORT 👉 Never Buy 👉 DELETE
Giuseppe Giannachi
Giuseppe Giannachi Feb 11, 2022 9:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What...?
Falah Alshaikh
Falah Alshaikh Mar 25, 2021 3:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Guy let buy more nakd
Batuhan Babür
Batuhan Babür Mar 25, 2021 12:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Rip who bought at 9 typical pump and dump
Batuhan Babür
Batuhan Babür Mar 25, 2021 12:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sell now pump amd dump
Alex Huawei
Alex Huawei Mar 25, 2021 12:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11 today
Batuhan Babür
Batuhan Babür Mar 25, 2021 12:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nope
Batuhan Babür
Batuhan Babür Mar 25, 2021 12:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nice tricking people dude
Simon Hemmes
SimonGiraf Mar 25, 2021 10:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
amazing rise.
Mike Swaditch
Mike Swaditch Mar 25, 2021 7:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
target price up from 19 to 35 listed as a hold for now
Brijesh Patel
Brijesh Patel Feb 08, 2021 1:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://finance.yahoo.com/news/2-strong-buy-penny-stocks-153448116.html Strong Buy rating & analysts prediction $20
JOHN AH
JOHN AH Jan 28, 2021 11:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good moment for buy more
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email